Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Wang, Zhigang ^a   Yan, Zhi ^a   Zhang, Bicheng ^a   Rao, Zhiguo ^a   Zhang, Yafei ^a   Liu, Jian ^a   Yu, Lifang ^a   Zhao, Yong ^a   Yang, Bo ^a   Wu, Tingting ^a   Gao, Jianfei ^a  

^a WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Clinical outcome; Gastric cancer; Gene signature; Microarray data; Prognostic predictor

Indexed keywords

CBL PROTEIN; DNA BINDING PROTEIN; F BOX PROTEIN; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN BCL 2; BCL2L13 PROTEIN, HUMAN; CORDON BLEU PROTEIN LIKE 1, HUMAN; CORDON-BLEU PROTEIN-LIKE 1, HUMAN; NCOA6 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; VERY ELDERLY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA-BINDING PROTEINS; F-BOX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR COACTIVATORS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880806142     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0678-5     Document Type: Article

References (38)

1. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010;182:1-17.
2. Souza RF, Spechler SJ. Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin. 2005;55:334-51.
3. Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol. 2011;106:1978-85.
4. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30:3507-15.
5. Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206:306-10.
6. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 2011;17:2693-701.
7. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol. 2006; 13:12-30.
8. Dirican A, Ekinci N, Avci A, Akyol M, Alacacioglu A, Kucukzeybek Y, et al. The effects of hematological parameters and tumor-infiltrating lymphocytes on prognosis in patients with gastric cancer. Cancer Biomark. 2013;13:11-20.
9. Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, et al. MicroRNA- 21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 2011-2012; 10:71-7.
10. Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, et al. A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res. 2013;33:1257-66.
11. Rossi E, Klersy C, Manca R, Zuffardi O, Solcia E. Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. Hum Pathol. 2011;42:1937-45.
12. Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, Takiguchi S, et al. Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer. 2008;99: 1307-15.
13. Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29:77-83.
14. Park Y, Kang MH, Seo HY, Park JM, Choi CW, Kim YH, et al. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. Med Oncol. 2010;27:1192-9.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-8.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001;98:5116-21.
17. Meiklejohn CD, Townsend JP. A Bayesian method for analysing spotted microarray data. Brief Bioinform. 2005;6:318-30.
18. Pepe MS, Longton G, Anderson GL, Schummer M. Selecting differentially expressed genes from microarray experiments. Biometrics. 2003;59:133-42.
19. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-8.
20. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99-115.
21. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, et al. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer. 2007; 96:631-8.
22. Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, et al. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119:1985-93.
23. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011;17:1850-7.
24. Wang G, Hu N, Yang HH, Wang L, Su H, Wang C, et al. Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in china. PLoS ONE. 2013;8:e63826.
25. Komatsu S, Ichikawa D, Okamoto K, Ikoma D, Tsujiura M, Shiozaki A, et al. Differences of the lymphatic distribution and surgical outcomes between remnant gastric cancers and primary proximal gastric cancers. J Gastrointest Surg. 2012;16:503-8.
26. Wilkinson NW, Howe J, Gay G, Patel-Parekh L, Scott-Conner C, Donohue J. Differences in the pattern of presentation and treatment of proximal and distal gastric cancer: results of the 2001 gastric patient care evaluation. Ann Surg Oncol. 2008;15:1644-50.
27. Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol. 2007;1:26-41.
28. Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, Edenfield H, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst. 2009;101:678-86.
29. Yamaji S, Zhang M, Zhang J, Endo Y, Bibikova E, Goff SP, et al. Hepatocyte-specific deletion of DDB1 induces liver regeneration and tumorigenesis. Proc Natl Acad Sci U S A. 2010;107: 22237-42.
30. Hu J, McCall CM, Ohta T, Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol. 2004;6:1003-9.
31. Yang SH, Seo MY, Jeong HJ, Jeung HC, Shin J, Kim SC, et al. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. Clin Cancer Res. 2005;11:612-20.
32. Li Q, Xu J. Identification and characterization of the alternatively spliced nuclear receptor coactivator-6 isoforms. Int J Biol Sci. 2011;7:505-16.
33. Mahajan MA, Samuels HH. Nuclear receptor coactivator/coregulator NCoA6 (NRC) is a pleiotropic coregulator involved in transcription, cell survival, growth and development. Nucl Recept Signal. 2008;6:e002.
34. Yi P, Zhang W, Zhai Z, Miao L, Wang Y, Wu M. Bcl-rambo beta, a special splicing variant with an insertion of an Alu-like cassette, promotes etoposide- and Taxol-induced cell death. FEBS Lett. 2003;534:61-8.
35. Holleman A, den Boer ML, de Menezes RX, Cheok MH, Cheng C, Kazemier KM, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood. 2006;107:769-76.
36. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, et al. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res. 2010;16:451-60.
37. Lu T, Jackson MW, Singhi AD, Kandel ES, Yang M, Zhang Y, et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NF-kappaB. Proc Natl Acad Sci U S A. 2009;106:16339-44.
38. Lu T, Jackson MW, Wang B, Yang M, Chance MR, Miyagi M, et al. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A. 2010;107:46-51.